Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in Cushing's Disease
NCT00088608Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2004
- Primary completion
- Jun 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in Cushing's disease (CD), sponsored by Novartis. Primary endpoint: Urinary Free Cortisol at 15 days. Started Apr 2004; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT00088608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088608.